(VIANEWS) – NEOEN (NEOEN.PA), NORWEGIAN AIR SHUT (NAS.OL), SPBK 1 ØSTLANDET (SPOL.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NEOEN (NEOEN.PA)
48.5% sales growth and 3.27% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €0.94.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 27.91. Meaning, the purchaser of the share is investing €27.91 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.27%.
Yearly Top and Bottom Value
NEOEN’s stock is valued at €26.24 at 17:20 EST, way under its 52-week high of €39.60 and way above its 52-week low of €21.80.
More news about NEOEN.
2. NORWEGIAN AIR SHUT (NAS.OL)
27.8% sales growth and 37.41% return on equity
Norwegian Air Shuttle ASA, together with its subsidiaries, provides air travel services in Norway and internationally. It is also involved in aircraft financing, leasing, and ownership activities; and cargo activities. It operates a fleet of 87 aircrafts. Norwegian Air Shuttle ASA was founded in 1993 and is headquartered in Fornebu, Norway.
Earnings Per Share
As for profitability, NORWEGIAN AIR SHUT has a trailing twelve months EPS of kr1.59.
PE Ratio
NORWEGIAN AIR SHUT has a trailing twelve months price to earnings ratio of 7.72. Meaning, the purchaser of the share is investing kr7.72 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.41%.
Sales Growth
NORWEGIAN AIR SHUT’s sales growth for the next quarter is 27.8%.
More news about NORWEGIAN AIR SHUT.
3. SPBK 1 ØSTLANDET (SPOL.OL)
21% sales growth and 12.35% return on equity
SpareBank 1 Østlandet provides various financial products and services to individuals, businesses, the public sector, clubs, and societies. The company operates through Retail, Corporate, and Organisation Market and Capital Market segments. The Retail segment provides financial services comprising of savings, money transfer, insurance, accident prevention, financing, money transfer, capital, and investment management services. The Corporate segment offers interest rate, currency hedging, and investment related services, as well as insurance services for property. The Organisation Market and Capital Market segment provides risk based advisory solutions to high-net-worth individuals and corporates, as well as engages in foreign currency services. SpareBank 1 Østlandet was founded in 1845 and is headquartered in Hamar, Norway. SpareBank 1 Østlandet operates as a subsidiary of Sparebankstiftelsen Hedmark.
Earnings Per Share
As for profitability, SPBK 1 ØSTLANDET has a trailing twelve months EPS of kr14.95.
PE Ratio
SPBK 1 ØSTLANDET has a trailing twelve months price to earnings ratio of 9.72. Meaning, the purchaser of the share is investing kr9.72 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.35%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20%, now sitting on 5.59B for the twelve trailing months.
Moving Average
SPBK 1 ØSTLANDET’s value is higher than its 50-day moving average of kr145.28 and above its 200-day moving average of kr134.54.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Mar 22, 2024, the estimated forward annual dividend rate is 7.8 and the estimated forward annual dividend yield is 5.36%.
Yearly Top and Bottom Value
SPBK 1 ØSTLANDET’s stock is valued at kr145.34 at 17:20 EST, under its 52-week high of kr151.32 and way higher than its 52-week low of kr120.20.
More news about SPBK 1 ØSTLANDET.
4. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through seven segments: Fishmeal, Fish Oil and Fish Feed; Freshwater FO; Freshwater SCT; Farming FO; Farming SCT; Services; and Sales & Other. The company's products include fresh and frozen whole salmon, fresh and frozen salmon fillets, fresh skin-packed salmon portions, frozen salmon portions and tails, frozen smoked salmon and salmon fillets, frozen salmon bits and pieces, frozen salmon off-cuts and belly flaps, frozen salmon heads, salmon backbones, and salmon skin under the Bakkafrost, 18 ISLANDS, HEIMLAND, BAKKA SALMON, NATIVE HEBRIDEAN, and LOCHLANDER brands. It is also involved in the production and sale of fishmeal, fish oil, and fish feed; production of eggs from breeding self-owned salmon strains; production of smolts; and on-growing of salmon. In addition, the company manages a fleet of farming service vessels; provides fish transportation, treatments, net cleaning, harvesting, freight ans logistical, and heavy marine support services; converts organic waste into biogas, heating, electricity, and fertilizers; produces styrofoam boxes; and optimizes the value creation and retention from the harvested fish. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr24.1.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 26.93. Meaning, the purchaser of the share is investing kr26.93 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 8.9% and positive 68.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 7.54B for the twelve trailing months.
Yearly Top and Bottom Value
BAKKAFROST’s stock is valued at kr649.00 at 17:20 EST, way below its 52-week high of kr776.50 and way higher than its 52-week low of kr414.60.
Moving Average
BAKKAFROST’s value is higher than its 50-day moving average of kr623.15 and above its 200-day moving average of kr629.09.
More news about BAKKAFROST.
5. SALMAR (SALM.OL)
10.5% sales growth and 17.68% return on equity
SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming Central Norway, Fish Farming Northern Norway, Icelandic Salmon, Sales & Industry, and SalMar Aker Ocean segments. It is involved in the broodstock, harvesting, processing, and smolt production activities. In addition, the company offers fish fillets and related products. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.
Earnings Per Share
As for profitability, SALMAR has a trailing twelve months EPS of kr27.35.
PE Ratio
SALMAR has a trailing twelve months price to earnings ratio of 20.91. Meaning, the purchaser of the share is investing kr20.91 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.68%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 272.3% and 45.3%, respectively.
More news about SALMAR.
6. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Moving Average
SANOFI’s value is way below its 50-day moving average of €101.07 and under its 200-day moving average of €92.98.
More news about SANOFI.
7. AXACTOR (ACR.OL)
5.2% sales growth and 9.72% return on equity
Axactor ASA, through its subsidiaries, operates as a debt management and collection company in Sweden, Finland, Germany, Italy, Norway, and Spain. It operates through two segments: Non-performing Loans and Third-Party Collection. The Non-performing Loans segment invests in portfolios of non-performing loans collected through amicable or legal proceedings. The Third-Party Collection segment provides debt collection services on behalf of third-party clients, which applies amicable and legal proceedings to collect the non-performing loans. This segment is also involved in helping creditors to prepare documentation for future legal proceedings against debtors; and handling of invoices between the invoice date and the default date and sending out reminders. Axactor ASA was incorporated in 1982 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, AXACTOR has a trailing twelve months EPS of kr0.77.
PE Ratio
AXACTOR has a trailing twelve months price to earnings ratio of 5.48. Meaning, the purchaser of the share is investing kr5.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.72%.
More news about AXACTOR.
